Mike80 personal page - To The Moon

Mike80

Mike80

No personal profile

13Follow

0Followers

0Topic

0Badge

2021-06-15

Good

@格隆汇:維亞生物發佈全年業績，內生增長+外延發展助推收入翻倍

2021-06-15

So so but great prospect

Sorry, the original content has been removed

2021-06-15

Good sharing

Sorry, the original content has been removed

2021-06-15

Vaccine right and stock to move to right high rise soon

Sorry, the original content has been removed

2021-06-15

Expecting...

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3586688746625767","uuid":"3586688746625767","gmtCreate":1623594723432,"gmtModify":1623730888730,"name":"Mike80","pinyin":"mike80","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":13,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.26","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":187022387,"gmtCreate":1623731329149,"gmtModify":1704209840478,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586688746625767","authorIdStr":"3586688746625767"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187022387","repostId":"344346040","repostType":1,"repost":{"id":344346040,"gmtCreate":1618380651780,"gmtModify":1704709933689,"author":{"id":"39105730803552","authorId":"39105730803552","name":"格隆汇","avatar":"https://static.tigerbbs.com/8774dfe20eceb38c9645128bb6e60684","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"39105730803552","authorIdStr":"39105730803552"},"themes":[],"title":"維亞生物發佈全年業績，內生增長+外延發展助推收入翻倍","htmlText":"3月30號，維亞生物科技控股集團公佈了截至2020年12月31日的年度業績報告，並召開了年度業績發佈會。報告期內，維亞生物(1873.HK)錄得總收入近7億元，同比上漲超過115%；毛利超過3億元，同比上漲超過95%；經調整後Non-IFRS淨利潤達2.52億元人民幣。其中，來自CFS業務的收入超過6億元，同比增長了146%；同時，CFS業務錄得淨利潤1.66億元，同比大增近45%；來自EFS業務的收入超過9000萬元，同比增長近20%；內生增長疊加外延併購，推動營收與客戶數量雙增長商業模式方面，維亞生物CFS(服務換現金)業務與EFS(服務換股權)業務的協同效益在2020年中得到了進一步的顯現。CFS與EFS業務的齊頭並進使得公司既可以通過藥物研發在短期獲得穩定的服務費現金流，又可以通過藥物項目的孵化在長期獲得投資收益。報告期內，維亞生物CFS業務收入同比大幅增長近150%至6億元以上，客戶數量超過1250家。其中，CFS-藥物發現服務客戶近550家，客戶囊括全球十大製藥公司以及名列Fierce Biotech’s Fierce 15的35家公司，且客戶留存率超過85%；CFS-CDMO業務(朗華)客戶超過700家，前十大客戶留存率更是達到了100%。EFS業務收入同比增長了近20%至9230萬元。2020年，維亞生物共審閱了超過800個早期項目；新增生物醫藥初創企業投資21家；完成了對10家已有孵化企業的追加投資。截至2020年12月31日，維亞生物總計投資孵化了67家生物醫藥初創公司，平均協議持股比例近20%。同時，孵化公司的在研管線共125條，研發進展順利，半數以上管線已進入PCC/IND-enabling階段，11條管線已進入臨牀階段。維亞生物在基於結構的新藥研發技術(SBDD)、基於片段的新藥發現技術(FBDD)、膜蛋白靶點新藥研發技術、以及基於親和力的化合物庫","listText":"3月30號，維亞生物科技控股集團公佈了截至2020年12月31日的年度業績報告，並召開了年度業績發佈會。報告期內，維亞生物(1873.HK)錄得總收入近7億元，同比上漲超過115%；毛利超過3億元，同比上漲超過95%；經調整後Non-IFRS淨利潤達2.52億元人民幣。其中，來自CFS業務的收入超過6億元，同比增長了146%；同時，CFS業務錄得淨利潤1.66億元，同比大增近45%；來自EFS業務的收入超過9000萬元，同比增長近20%；內生增長疊加外延併購，推動營收與客戶數量雙增長商業模式方面，維亞生物CFS(服務換現金)業務與EFS(服務換股權)業務的協同效益在2020年中得到了進一步的顯現。CFS與EFS業務的齊頭並進使得公司既可以通過藥物研發在短期獲得穩定的服務費現金流，又可以通過藥物項目的孵化在長期獲得投資收益。報告期內，維亞生物CFS業務收入同比大幅增長近150%至6億元以上，客戶數量超過1250家。其中，CFS-藥物發現服務客戶近550家，客戶囊括全球十大製藥公司以及名列Fierce Biotech’s Fierce 15的35家公司，且客戶留存率超過85%；CFS-CDMO業務(朗華)客戶超過700家，前十大客戶留存率更是達到了100%。EFS業務收入同比增長了近20%至9230萬元。2020年，維亞生物共審閱了超過800個早期項目；新增生物醫藥初創企業投資21家；完成了對10家已有孵化企業的追加投資。截至2020年12月31日，維亞生物總計投資孵化了67家生物醫藥初創公司，平均協議持股比例近20%。同時，孵化公司的在研管線共125條，研發進展順利，半數以上管線已進入PCC/IND-enabling階段，11條管線已進入臨牀階段。維亞生物在基於結構的新藥研發技術(SBDD)、基於片段的新藥發現技術(FBDD)、膜蛋白靶點新藥研發技術、以及基於親和力的化合物庫","text":"3月30號，維亞生物科技控股集團公佈了截至2020年12月31日的年度業績報告，並召開了年度業績發佈會。報告期內，維亞生物(1873.HK)錄得總收入近7億元，同比上漲超過115%；毛利超過3億元，同比上漲超過95%；經調整後Non-IFRS淨利潤達2.52億元人民幣。其中，來自CFS業務的收入超過6億元，同比增長了146%；同時，CFS業務錄得淨利潤1.66億元，同比大增近45%；來自EFS業務的收入超過9000萬元，同比增長近20%；內生增長疊加外延併購，推動營收與客戶數量雙增長商業模式方面，維亞生物CFS(服務換現金)業務與EFS(服務換股權)業務的協同效益在2020年中得到了進一步的顯現。CFS與EFS業務的齊頭並進使得公司既可以通過藥物研發在短期獲得穩定的服務費現金流，又可以通過藥物項目的孵化在長期獲得投資收益。報告期內，維亞生物CFS業務收入同比大幅增長近150%至6億元以上，客戶數量超過1250家。其中，CFS-藥物發現服務客戶近550家，客戶囊括全球十大製藥公司以及名列Fierce Biotech’s Fierce 15的35家公司，且客戶留存率超過85%；CFS-CDMO業務(朗華)客戶超過700家，前十大客戶留存率更是達到了100%。EFS業務收入同比增長了近20%至9230萬元。2020年，維亞生物共審閱了超過800個早期項目；新增生物醫藥初創企業投資21家；完成了對10家已有孵化企業的追加投資。截至2020年12月31日，維亞生物總計投資孵化了67家生物醫藥初創公司，平均協議持股比例近20%。同時，孵化公司的在研管線共125條，研發進展順利，半數以上管線已進入PCC/IND-enabling階段，11條管線已進入臨牀階段。維亞生物在基於結構的新藥研發技術(SBDD)、基於片段的新藥發現技術(FBDD)、膜蛋白靶點新藥研發技術、以及基於親和力的化合物庫","images":[{"img":"https://static.tigerbbs.com/12391161162a76fa321bc301dcdb79c3"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344346040","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187023841,"gmtCreate":1623731230883,"gmtModify":1704209835455,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586688746625767","authorIdStr":"3586688746625767"},"themes":[],"htmlText":"So so but great prospect","listText":"So so but great prospect","text":"So so but great prospect","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187023841","repostId":"1167323938","repostType":4,"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187062470,"gmtCreate":1623731012690,"gmtModify":1704209827654,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586688746625767","authorIdStr":"3586688746625767"},"themes":[],"htmlText":"Good sharing&nbsp;","listText":"Good sharing&nbsp;","text":"Good sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187062470","repostId":"1175897310","repostType":4,"isVote":1,"tweetType":1,"viewCount":308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187068895,"gmtCreate":1623730901817,"gmtModify":1704209824578,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586688746625767","authorIdStr":"3586688746625767"},"themes":[],"htmlText":"Vaccine right and stock to move to right high rise soon","listText":"Vaccine right and stock to move to right high rise soon","text":"Vaccine right and stock to move to right high rise soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187068895","repostId":"2143736088","repostType":4,"isVote":1,"tweetType":1,"viewCount":289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187085134,"gmtCreate":1623730650628,"gmtModify":1704209814855,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586688746625767","authorIdStr":"3586688746625767"},"themes":[],"htmlText":"Expecting...","listText":"Expecting...","text":"Expecting...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187085134","repostId":"1138219989","repostType":4,"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":187068895,"gmtCreate":1623730901817,"gmtModify":1704209824578,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586688746625767","authorIdStr":"3586688746625767"},"themes":[],"htmlText":"Vaccine right and stock to move to right high rise soon","listText":"Vaccine right and stock to move to right high rise soon","text":"Vaccine right and stock to move to right high rise soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187068895","repostId":"2143736088","repostType":4,"isVote":1,"tweetType":1,"viewCount":289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187085134,"gmtCreate":1623730650628,"gmtModify":1704209814855,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586688746625767","authorIdStr":"3586688746625767"},"themes":[],"htmlText":"Expecting...","listText":"Expecting...","text":"Expecting...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187085134","repostId":"1138219989","repostType":4,"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187022387,"gmtCreate":1623731329149,"gmtModify":1704209840478,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586688746625767","authorIdStr":"3586688746625767"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187022387","repostId":"344346040","repostType":1,"repost":{"id":344346040,"gmtCreate":1618380651780,"gmtModify":1704709933689,"author":{"id":"39105730803552","authorId":"39105730803552","name":"格隆汇","avatar":"https://static.tigerbbs.com/8774dfe20eceb38c9645128bb6e60684","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"39105730803552","authorIdStr":"39105730803552"},"themes":[],"title":"維亞生物發佈全年業績，內生增長+外延發展助推收入翻倍","htmlText":"3月30號，維亞生物科技控股集團公佈了截至2020年12月31日的年度業績報告，並召開了年度業績發佈會。報告期內，維亞生物(1873.HK)錄得總收入近7億元，同比上漲超過115%；毛利超過3億元，同比上漲超過95%；經調整後Non-IFRS淨利潤達2.52億元人民幣。其中，來自CFS業務的收入超過6億元，同比增長了146%；同時，CFS業務錄得淨利潤1.66億元，同比大增近45%；來自EFS業務的收入超過9000萬元，同比增長近20%；內生增長疊加外延併購，推動營收與客戶數量雙增長商業模式方面，維亞生物CFS(服務換現金)業務與EFS(服務換股權)業務的協同效益在2020年中得到了進一步的顯現。CFS與EFS業務的齊頭並進使得公司既可以通過藥物研發在短期獲得穩定的服務費現金流，又可以通過藥物項目的孵化在長期獲得投資收益。報告期內，維亞生物CFS業務收入同比大幅增長近150%至6億元以上，客戶數量超過1250家。其中，CFS-藥物發現服務客戶近550家，客戶囊括全球十大製藥公司以及名列Fierce Biotech’s Fierce 15的35家公司，且客戶留存率超過85%；CFS-CDMO業務(朗華)客戶超過700家，前十大客戶留存率更是達到了100%。EFS業務收入同比增長了近20%至9230萬元。2020年，維亞生物共審閱了超過800個早期項目；新增生物醫藥初創企業投資21家；完成了對10家已有孵化企業的追加投資。截至2020年12月31日，維亞生物總計投資孵化了67家生物醫藥初創公司，平均協議持股比例近20%。同時，孵化公司的在研管線共125條，研發進展順利，半數以上管線已進入PCC/IND-enabling階段，11條管線已進入臨牀階段。維亞生物在基於結構的新藥研發技術(SBDD)、基於片段的新藥發現技術(FBDD)、膜蛋白靶點新藥研發技術、以及基於親和力的化合物庫","listText":"3月30號，維亞生物科技控股集團公佈了截至2020年12月31日的年度業績報告，並召開了年度業績發佈會。報告期內，維亞生物(1873.HK)錄得總收入近7億元，同比上漲超過115%；毛利超過3億元，同比上漲超過95%；經調整後Non-IFRS淨利潤達2.52億元人民幣。其中，來自CFS業務的收入超過6億元，同比增長了146%；同時，CFS業務錄得淨利潤1.66億元，同比大增近45%；來自EFS業務的收入超過9000萬元，同比增長近20%；內生增長疊加外延併購，推動營收與客戶數量雙增長商業模式方面，維亞生物CFS(服務換現金)業務與EFS(服務換股權)業務的協同效益在2020年中得到了進一步的顯現。CFS與EFS業務的齊頭並進使得公司既可以通過藥物研發在短期獲得穩定的服務費現金流，又可以通過藥物項目的孵化在長期獲得投資收益。報告期內，維亞生物CFS業務收入同比大幅增長近150%至6億元以上，客戶數量超過1250家。其中，CFS-藥物發現服務客戶近550家，客戶囊括全球十大製藥公司以及名列Fierce Biotech’s Fierce 15的35家公司，且客戶留存率超過85%；CFS-CDMO業務(朗華)客戶超過700家，前十大客戶留存率更是達到了100%。EFS業務收入同比增長了近20%至9230萬元。2020年，維亞生物共審閱了超過800個早期項目；新增生物醫藥初創企業投資21家；完成了對10家已有孵化企業的追加投資。截至2020年12月31日，維亞生物總計投資孵化了67家生物醫藥初創公司，平均協議持股比例近20%。同時，孵化公司的在研管線共125條，研發進展順利，半數以上管線已進入PCC/IND-enabling階段，11條管線已進入臨牀階段。維亞生物在基於結構的新藥研發技術(SBDD)、基於片段的新藥發現技術(FBDD)、膜蛋白靶點新藥研發技術、以及基於親和力的化合物庫","text":"3月30號，維亞生物科技控股集團公佈了截至2020年12月31日的年度業績報告，並召開了年度業績發佈會。報告期內，維亞生物(1873.HK)錄得總收入近7億元，同比上漲超過115%；毛利超過3億元，同比上漲超過95%；經調整後Non-IFRS淨利潤達2.52億元人民幣。其中，來自CFS業務的收入超過6億元，同比增長了146%；同時，CFS業務錄得淨利潤1.66億元，同比大增近45%；來自EFS業務的收入超過9000萬元，同比增長近20%；內生增長疊加外延併購，推動營收與客戶數量雙增長商業模式方面，維亞生物CFS(服務換現金)業務與EFS(服務換股權)業務的協同效益在2020年中得到了進一步的顯現。CFS與EFS業務的齊頭並進使得公司既可以通過藥物研發在短期獲得穩定的服務費現金流，又可以通過藥物項目的孵化在長期獲得投資收益。報告期內，維亞生物CFS業務收入同比大幅增長近150%至6億元以上，客戶數量超過1250家。其中，CFS-藥物發現服務客戶近550家，客戶囊括全球十大製藥公司以及名列Fierce Biotech’s Fierce 15的35家公司，且客戶留存率超過85%；CFS-CDMO業務(朗華)客戶超過700家，前十大客戶留存率更是達到了100%。EFS業務收入同比增長了近20%至9230萬元。2020年，維亞生物共審閱了超過800個早期項目；新增生物醫藥初創企業投資21家；完成了對10家已有孵化企業的追加投資。截至2020年12月31日，維亞生物總計投資孵化了67家生物醫藥初創公司，平均協議持股比例近20%。同時，孵化公司的在研管線共125條，研發進展順利，半數以上管線已進入PCC/IND-enabling階段，11條管線已進入臨牀階段。維亞生物在基於結構的新藥研發技術(SBDD)、基於片段的新藥發現技術(FBDD)、膜蛋白靶點新藥研發技術、以及基於親和力的化合物庫","images":[{"img":"https://static.tigerbbs.com/12391161162a76fa321bc301dcdb79c3"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344346040","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187023841,"gmtCreate":1623731230883,"gmtModify":1704209835455,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586688746625767","authorIdStr":"3586688746625767"},"themes":[],"htmlText":"So so but great prospect","listText":"So so but great prospect","text":"So so but great prospect","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187023841","repostId":"1167323938","repostType":4,"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187062470,"gmtCreate":1623731012690,"gmtModify":1704209827654,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586688746625767","authorIdStr":"3586688746625767"},"themes":[],"htmlText":"Good sharing&nbsp;","listText":"Good sharing&nbsp;","text":"Good sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187062470","repostId":"1175897310","repostType":4,"isVote":1,"tweetType":1,"viewCount":308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}